The satellite symposium at EHA2022 was chaired by Paolo Ghia joined by Federico Pea, Barbara Eichhorst, Shirley D’Sa and Ramón García Sanz. They discussed next-generation BTK inhibitors in the treatment of B-cell malignancies.
Report on updates in the treatment of B-cell malignancies presented at ASH 2021.
SEQUOIA is a global phase 3, open label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in participants with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).
BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to fight cancer. Get up-to-date with the BeiGene hematology pipeline and clinical trials.
Zanubrutinib (BGB-3111) is a Bruton’s tyrosine kinase inhibitor (BTKi), currently being evaluated in a broad late-stage clinical trials program globally to treat various B-cell malignancies.
